Main Article Content
Purpose: To evaluate the effect of trimetazidine on ventricular remodeling and serum levels of cystatin C and endothelin-1 in patients with chronic heart failure (CHF).
Methods: A total of 96 patients with CHF were randomly divided into two groups, given either conventional treatment (control group) or conventional treatment plus trimetazidine (study group) for 6 months. Clinical efficacy was compared between the two groups. Left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) were measured using cardiac echocardiography before and after treatment. Patients were
recorded at 6 MVT before and after treatment. An automatic biochemical analyzer was used to assay serum Cys C levels before and after treatment. Serum levels of ET-1, galactose agglutinin-3 (GAL-3), brain natriuretic peptide (BNP) and heart natriuretic peptide (ANP) were determined by enzyme-linked immunosorbent assay (ELISA) before and after treatment. Incidence of adverse events in CHF patients was compared between groups.
Results: Study group had a significantly higher level of treatment effectiveness (91.67 %) and better improvement in left ventricular ejection fraction, left ventricular end-systolic diameter and left ventricular end-diastolic diameter than control group (p < 0.05). Serum levels of serum cystatin C, endothelin-1 and other biomarkers were also significantly lower (p < 0.05) in study group. Re-hospitalization rate was also lower in study group.
Conclusion: Trimetazidine exerts a therapeutic effect on CHF patients, effectively improves cardiac function and reduces the rate of re-hospitalization.